drugset / Trial / NCT03087032
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
RandomizedParallel-groupOpen-labelTreatment
Summary
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Timeline
- Start
- 2019-01-10
- Primary completion
- 2025-01-15
- Completion
- 2025-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.8 mg | — |
| Comparator | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |